Phaseline

Targets › AQP1

AQP1 (Aquaporin-1): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 1, 1 Phase 2; Gastroenterology, Oncology; next expected readout Jun 2027.

Forms a water channel that facilitates the transport of water across cell membranes, playing a crucial role in water homeostasis in various tissues. Could also be permeable to small solutes including hydrogen peroxide, glycerol and gases such as amonnia (NH3), nitric oxide (NO) and carbon dioxide (CO2). (UniProt, P29972)

Open in Phaseline: the race on AQP1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
MeiraGTxAAV2-hAQP1
AAV2-delivered aquaporin-1 gene therapy
AQP1Phase 2Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid GlandsJun 2027
RiboX TherapeuticsRXRG001
Circular RNA encoding human aquaporin 1 delivered via lipid nanoparticle
AQP1Phase 1Radiation-Induced Xerostomia and HyposalivationAug 2027

Conditions

Radiation-Induced Xerostomia and Hyposalivation (1) Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands (1)

Modalities

protein or peptide (1), other (1)

Companies

RiboX Therapeutics (1) MeiraGTx (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.